Ann Pediatr Endocrinol Metab.  2023 Dec;28(4):235-236. 10.6065/apem.2322098edi010.

Commentary on "Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study"

• Lim HH

• KMID: 2549314
• DOI: http://doi.org/10.6065/apem.2322098edi010

Reference

References

1. Garvick S, Altenburg L, Dunlap B, Fisher A, Watson A, Gregory T. Diagnosis and management of type 2 diabetes in children. JAAPA. 2022; 35:16–22.

2. Ha J, Oh YR, Kang E, Nam HK, Rhie YJ, Lee KH. Single point insulin sensitivity estimator for predicting type 2 diabetes mellitus in obese adolescents. Ann Pediatr Endocrinol Metab. 2022; 27:201–6.

3. Michaliszyn SF, Mari A, Lee S, Bacha F, Tfayli H, Farchoukh L, et al. β-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes. 2014; 63:3846–55.

4. Kim J, Lee J. Role of obesity-induced inflammation in the development of insulin resistance and type 2 diabetes: history of the research and remaining questions. Ann Pediatr Endocrinol Metab. 2021; 26:1–13.

5. Tamborlane W, Shehadeh N. Unmet needs in the treatment of childhood type 2 diabetes: a narrative review. Adv Ther. 2023; 40:4711–20.

6. Constantino MI, Molyneaux L, Limacher-Gisler F, Al-Saeed A, Luo C, Wu T, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 2013; 36:3863–9.

7. Berman C, Vidmar AP, Chao LC. Glucagon-like Peptide-1 receptor agonists for the treatment of type 2 diabetes in youth. touchREV Endocrinol. 2023; 19:38–45.

8. Shah AS, Zeitler PS, Wong J, Pena AS, Wicklow B, Arslanian S, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. Pediatr Diabetes. 2022; 23:872–902.

9. Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, Tesfaldet B, et al. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021; 385:416–26.

10. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021; 46:101102.

11. Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, et al. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol. 2022; 10:341–50.

12. Seo JY, Lee CG, Choi H, Lee HK, Lee SY, Kim HJ, et al. Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study. Ann Pediatr Endocrinol Metab Ann Pediatr Endocrinol Metab. 2023; 28:296–301.